奈达铂联合多西他赛并同期放疗治疗不可手术食管癌的疗效

Efficacy of nedaplatin combined with docetaxel and concurrent radiotherapy for patients with unresectable esophageal cancer

目的探讨奈达铂联合多西他赛并同期放疗治疗不可手术食管癌的临床治疗效果。方法选取自2014年7月至2015年12月在肿瘤科接受治疗的中晚期食管癌确诊患者93例作为研究对象,采用随机数字表法将所有研究对象分为观察组和对照组。对照组给予顺铂联合5-氟尿嘧啶化疗和同步放射治疗,观察组给予奈达铂联合多西他赛化疗以及与对照组同等的同步放射治疗。比较2组患者血清p53抗体、鳞状细胞癌抗原(SCCAg)、癌胚抗原(CEA)水平,临床疗效,以及治疗后2年累计生存率。结果治疗后2组患者血清p53抗体、SCCAg和CEA水平均显著低于治疗前,观察组患者血清p53抗体、SCCAg和CEA水平均显著低于对照组,且以上差异均有统计学意义(P<0.05);观察组患者治疗总有效率明显高于对照组,且差异具有统计学意义(χ~2=4.658,P<0.05);治疗后观察组食管癌患者的2年累计生存率显著高于对照组,且差异有统计学意义(53.33%vs 27.08%, Log-rank χ~2=4.532,P<0.05)。结论奈达铂联合多西他赛并同期放疗治疗不可手术食管癌的临床治疗效果较好,且预后也较好,值得在临床推广应用。

AIM To investigate the clinical efficacy of nedaplatin combined with docetaxel and concurrent radiotherapy in the treatment of unresectable esophageal cancer. METHODS Totally 93 patients with advanced esophageal cancer who were treated in the oncology department of our hospital from July 2014 to December 2015 were selected as the research subjects. All the subjects were divided into the observation group and the control group by the random number table method. The control group was treated with cisplatin combined with 5-fluoroura-cil chemotherapy and synchrotron radiation therapy. The observation group was treated with nedaplatin combined with docetaxel chemotherapy and the control group with the same synchrotron radiation therapy. The serum levels of p53 antibody, squamous cell carcinoma antigen ( SCCAg) and carcinoembryonic antigen ( CEA), clinical efficacy and 2-year cumulative survival rate were compared between 2 groups. RESULTS After treatment, the serum levels of p53 , SCCAg and CEA in 2 groups were significantly lower than those before treatment, and the levels of serum p53 antibody, SCCAg and CEA in the observation group were significantly lower than those in the control group (P <0.05). The total effective rate of the patients in the observation group was significantly higher than that in the control group(x^2 =4. 658 , P <0. 05 ), and the difference was statistically significant ( P < 0. 05 ). The 2-year cumulative survival rate (53. 33% vs 27. 08%, Log-rank x^2=4. 532, P < 0. 05 ) in the patients with esophageal cancer was significantly higher than that in the control group after treatment, and there was a statistically significant difference ( P < 0. 05 ). CONCLUSION Nedaplatin combined with docetaxel and concurrent radiotherapy in the treatment of unresectable esophageal cancer is effective and has a good prognosis. It is worthy of clinical application.